基于CT的影像组学特征用于术前区分头颈部鳞状细胞癌程序性死亡配体1高表达与低表达
本研究纳入两个中心共179例经免疫组化检测肿瘤PD-L1表达的头颈部鳞状细胞癌患者,分为训练集122例(PD-L1高表达55例、低表达67例)和外部验证集57例(高表达26例、低表达31例),基于增强CT构建影像组学特征并经受试者工作特征分析评估,训练集与验证集区分PD-L1高、低表达的AUC分别为0.889和0.834。
要点
- 基于增强CT的影像组学特征在训练集区分PD-L1高、低表达的AUC为0.889。
- 外部验证集区分PD-L1高、低表达的AUC为0.834。
- 最终选取6个特征构建影像组学特征模型。
核心结论
- 所构建的基于增强CT的影像组学特征模型在区分头颈部鳞状细胞癌患者PD-L1高表达与低表达状态方面表现良好,可能有助于筛选最能从抗PD-L1免疫治疗中获益的头颈部鳞状细胞癌患者。
研究设计与样本
- 研究纳入两个中心共179例接受肿瘤PD-L1免疫组化检查的头颈部鳞状细胞癌患者,分为训练集122例(PD-L1高表达55例、低表达67例)和外部验证集57例(PD-L1高表达26例、低表达31例),采用最小绝对收缩和选择算子法筛选增强CT影像组学特征,并以受试者工作特征分析评估模型性能。
诊断标准与关键数值
- 训练集影像组学特征区分PD-L1高表达与低表达的AUC为0.889。
- 外部验证集影像组学特征区分PD-L1高表达与低表达的AUC为0.834。
- 最终选取6个特征构建基于增强CT图像的影像组学特征。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: Accurate prediction of the expression level of programmed death ligand 1 (PD-L1) in head and neck squamous cell carcinoma (HNSCC) is crucial before immunotherapy. The purpose of this study was to construct and validate a contrast-enhanced computed tomography (CECT)-based radiomics signature to discriminate between high and low expression status of PD-L1.
METHODS: A total of 179 HNSCC patients who underwent immunohistochemical examination of tumor PD-L1 expression at one of two centers were enrolled in this study and divided into a training set (n = 122; 55 high PD-L1 expression and 67 low PD-L1 expression) and an external validation set (n = 57; 26 high PD-L1 expression and 31 low PD-L1 expression). The least absolute shrinkage and selection operator method was used to select the key features for a CECT-image-based radiomics signature. The performance of the radiomics signature was assessed using receiver operating characteristics analysis.
RESULTS: Six features were finally selected to construct the radiomics signature. The performance of the radiomics signature in the discrimination between high and low PD-L1 expression status was good in both the training and validation sets, with areas under the receiver operating characteristics curve of 0.889 and 0.834 for the training and validation sets, respectively.
CONCLUSIONS: The constructed CECT-based radiomics signature model showed favorable performance for discriminating between high and low PD-L1 expression status in HNSCC patients. It may be useful for screening out those patients with HNSCC who can best benefit from anti-PD-L1 immunotherapy.
引用
- Zheng, Zhan, Yuan, et al. A CT-based radiomics signature for preoperative discrimination between high and low expression of programmed death ligand 1 in head and neck squamous cell carcinoma. Eur J Radiol. 2021. PMID: 34890937. doi:10.1016/j.ejrad.2021.110093
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。